【摘要】 目的:探讨HER-2/neu基因在鼻咽癌中的表达及其临床意义。方法:采用免疫组化法测定HER2/neu基因蛋白的表达。结果:69例鼻咽癌病人中52%(36/69)有HER2/neu基因蛋白表达。这种过表达与肿瘤分期、局部淋巴结和远处脏器转移以及5年总生存期、3年无病生存期均无相关性。同一病例原发病灶和复发或转移灶HER2/neu基因蛋白的表达较一致。HER2/neu基因蛋白过表达对鼻咽癌化疗的反应性不产生影响。结论:在鼻咽癌,HER2/neu基因蛋白过表达的临床意义不明,HER2/neu基因蛋白能否成为治疗新的靶点还有待进一步研究。更多还原

【Abstract】 Objective: To explore a new biological prognostic indicator and strategy of treatment of the patients with nasopharyngeal cancer. Method: HER 2/neu protein expression of archival samples of nasopharyngeal cancer using immunohistochemistry. Results: HER 2/neu expression was detected in 52%(36/69) of samples in 69 patients with nasopharyngeal cancer. HER 2/neu overexpression did not correlate with tumor stage, locoregional lymph node and distant internal organs metastases, and five years overall survival or three years diseases free survival. HER 2/neu expression of the same patient was more consistent in primary and recurrent or metastatic pathologic tissue. HER 2/neu overexpression did not affect the response to chemotherapy in the patients with nasopharyngeal cancer. Conclusion: The clinical significance of HER 2/neu overexpression is not yet clear, and whether HER 2/neu protein could become new target of treatmeat in nasopharyngeal cancer need to be further investigated.更多还原